The forecasted standardized mortality rate for liver malignant neoplasms among women in the US shows a gradual upward trend from 2024 to 2028, moving from 5.7 to 6.0 deaths per hundred thousand. The year-on-year percentage increase from 2024 to 2025 is approximately 1.75%, and the same trend continues consistently until 2027. By 2028, the rate stabilizes at 6.0, indicating a plateau in mortality growth. The Compound Annual Growth Rate (CAGR) from 2024 to 2028 is estimated at around 1.28%, reflecting modest annual increases.
Future trends to watch for include advances in early detection and treatment protocols, which may impact mortality rates. Changes in lifestyle, liver disease prevalence, and healthcare policies also play crucial roles in shaping these trends. Additionally, technological innovations in medical research could potentially alter mortality forecasts by improving survival rates.
